Lilly and Novo Face Off at ADA 2026 as Others Seek to Compete in Obesity

Why It Matters

Obesity drugs are becoming the fastest‑growing therapeutic segment, reshaping pharma pipelines and revenue streams, while safety and differentiation will determine which companies secure market leadership.

Key Takeaways

• Lilly's retatrutide achieved 28.3% weight loss in Phase 3 TRIUMPH‑1
• Retatrutide showed dysesthesia in over 20% of patients at 20 mg
• Novo's CagriSema cut 23% weight, behind Zepbound’s 25.5%
• Boehringer's survodutide posted 16.6% loss, less competitive than dual‑agonists
• Structure and Viking unveil oral GLP‑1 pills achieving 11‑13% weight loss

Pulse Analysis

The obesity therapeutic arena is undergoing a seismic shift, with IQVIA forecasting global sales of $92 billion this year and a potential $200 billion by 2027. This surge reflects a broader reallocation of R&D dollars, as weight‑loss drugs now account for a quarter of pharma pipeline value, eclipsing oncology. Investors are watching the ADA 2026 conference closely, expecting the data presented there to set the next wave of market dynamics and inform pricing strategies for a category that promises multi‑billion‑dollar revenues.

Lilly's retatrutide, a triple‑G agonist, delivered headline‑grabbing 28.3% mean weight loss over 80 weeks, a figure comparable to bariatric surgery outcomes. However, the emergence of dysesthesia in more than 20% of patients at the 20 mg dose raises concerns about tolerability, a factor that could limit its commercial appeal despite potency. Novo Nordisk's CagriSema, a fixed‑dose GLP‑1/amylin combo, posted a solid 23% reduction but fell short of Zepbound’s 25.5% in the REDEFINE‑4 head‑to‑head study. The mixed efficacy and safety profiles underscore a trade‑off that will influence formulary decisions and payer negotiations as both giants vie for first‑line status.

Beyond the duopoly, a crowded field of challengers is positioning themselves for a slice of the market. Boehringer Ingelheim's survodutide showed a 16.6% loss, while Roche’s CT‑388 and Amgen’s MariTide aim to differentiate through liver‑fat benefits and dosing convenience. Meanwhile, nimble biotechs like Structure Therapeutics and Viking Therapeutics are pushing oral GLP‑1 candidates that achieved 11‑13% weight reductions, promising a more patient‑friendly route. As safety data mature and real‑world outcomes emerge, the next few years will likely see consolidation around the most effective and tolerable agents, with investors tracking not just efficacy numbers but also the ability to navigate regulatory scrutiny and payer landscapes.